FATP2 pharmacological inhibition impaired the suppressive activities of tumor associated neutrophils and delayed tumor progression, both alone and in synergy with other forms of immunotherapy (108), suggesting novel avenues for cancer treatment. This evidence concerns the gene SLC27A2 and neoplasm.